Topiramate in the treatment of trichotillomania: An open-label pilot study

Simple item page
dc.contributor.authorLochner C.
dc.contributor.authorSeedat S.
dc.contributor.authorNiehaus D.J.H.
dc.contributor.authorStein D.J.
dc.date.accessioned2011-05-15T15:59:17Z
dc.date.available2011-05-15T15:59:17Z
dc.date.issued2006
dc.description.abstractThere is a need for an effective medication for the treatment of trichotillomania (TTM), which is an impulse control disorder characterized by chronic hair-pulling. Topiramate has shown promising results in the treatment of impulse-control disorders. The present open-label pilot study investigated the efficacy and safety of topiramate in 14 adults with TTM. Patients received 16 weeks of flexible dose treatment (50-250 mg/day), followed by a flexible dose taper over 2-4 weeks. The primary outcome measure was the Massachusetts General Hospital Hair-Pulling Scale (HPS), whereas secondary outcome measures were the Clinical Global Impression (CGI) Scale, the Montgomery-Asberg Depression Rating Scale, the Hamilton Rating Scale for Anxiety and the Disability Profile. A repeated measures analysis of variance on the intent-to-treat sample was implemented to evaluate treatment response. The primary outcome measure (HPS) indicated that the severity of hair-pulling in adults with TTM who completed the 16-week study (n=9) decreased significantly from baseline to the treatment endpoint (F=5.05; P=0.0002). Although the CGI-Improvement scores suggested that hair-pulling was not significantly reduced, six of nine trial completers were classified as responders. None of the other measures showed significant differences compared to baseline. Five patients dropped out owing to adverse effects. These results suggest that topiramate may be useful in the treatment of TTM. Future studies should investigate the efficacy of topiramate in an appropriately powered randomized placebo-controlled trial. © 2006 Lippincott Williams & Wilkins.
dc.description.versionArticle
dc.identifier.citationInternational Clinical Psychopharmacology
dc.identifier.citation21
dc.identifier.citation5
dc.identifier.issn2681315
dc.identifier.other10.1097/00004850-200609000-00002
dc.identifier.urihttp://hdl.handle.net/10019.1/11099
dc.subjecttopiramate
dc.subjectadult
dc.subjectanalysis of variance
dc.subjectanomia
dc.subjectanxiety
dc.subjectarticle
dc.subjectblurred vision
dc.subjectclinical article
dc.subjectClinical Global Impression scale
dc.subjectclinical trial
dc.subjectcognitive defect
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdecreased appetite
dc.subjectdepression
dc.subjectdiplopia
dc.subjectdisease severity
dc.subjectdose response
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectfemale
dc.subjectHamilton scale
dc.subjectheadache
dc.subjecthuman
dc.subjectimpulse control disorder
dc.subjectinsomnia
dc.subjectlanguage disability
dc.subjectmale
dc.subjectmemory disorder
dc.subjectmental concentration
dc.subjectmental health
dc.subjectmigraine
dc.subjectmyalgia
dc.subjectnausea
dc.subjectoutcome assessment
dc.subjectparesthesia
dc.subjectpriority journal
dc.subjectrating scale
dc.subjectside effect
dc.subjectslurred speech
dc.subjectspeech disorder
dc.subjecttreatment response
dc.subjecttrichotillomania
dc.subjectweight reduction
dc.subjectxerostomia
dc.subjectAdult
dc.subjectFemale
dc.subjectFructose
dc.subjectHumans
dc.subjectMale
dc.subjectPilot Projects
dc.subjectTrichotillomania
dc.titleTopiramate in the treatment of trichotillomania: An open-label pilot study
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications